Skip to content

Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass

A Comparison Between the Effect of Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia on Cerebral Perfusion Guided by Near Infra-red Spectroscopy in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass Graft Surgery: (A Randomized Controlled Study)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07248202
Enrollment
40
Registered
2025-11-25
Start date
2025-12-01
Completion date
2026-07-01
Last updated
2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease (CAD), Left Ventricular (LV) Systolic Dysfunction, Induction Anesthesia, Coronary Bypass Graft Surgery, Ketamine, Fentanyl, Lidocaine

Brief summary

This study compares ketamine/fentanyl versus ketamine/lidocaine in term of their impact on cerebral perfusion during CABG. No prior data address these effects, and the goal is to identify the induction regimen that better preserves cerebral oxygenation.

Detailed description

Cerebral oximetry monitoring using Near-Infrared Spectroscopy (NIRS) bilaterally (CASMED, Module series Fore-sight Elite, \[SN\]1931030) will be applied to all patients. Resting baseline rSO2 values will be obtained after waiting at least 1 min after placement of sensors once values had stabilized. Bispectral index (BIS) will be applied. The baseline data for the heart rate, systolic, diastolic, and mean systemic arterial pressures will be recorded from the average ward measurement the day before surgery. in all patients, ketamine will be injected slowly at 1.5 mg/kg in 0.25 mg/kg increments until clinical loss of consciousness. Clinical loss of consciousness (defined as no response to auditory command) will be assessed by asking the patients repeatedly to open their eyes. After loss of consciousness, atracurium 0.5 mg/kg will be administered to facilitate tracheal intubation. Tachycardia and hypertension, (20% increase heart rate, blood pressure from baseline reading) will be managed by a 50 mcg-bolus of Fentanyl. Anesthesia will be maintained by isoflurane (adjusted to maintain end-tidal minimal alveolar concentration of 1-1.2 %) in oxygen/air mixture. Mechanical ventilation will be adjusted to maintain end-tidal CO2 of 35-40 mmHg Any episode of hypotension (defined as mean arterial pressure \[MAP\] \< 70% of the baseline reading and/or MAP \<65mmHg, will be managed by 5 mcg norepinephrine (which could be repeated if hypotension persists for 1-min, NE infusion will be started if persisted after 3 boluses). Ephedrine bolus will be give if hypotension was associated with bradycardia.

Interventions

patients will receive 1 mcg/kg of Fentanyl (10 mcg/mL).

DRUGlidocaine

patients will receive 1 mg/kg lidocaine (10mg/mL)

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with coronary artery disease * with moderate to severe left ventricular dysfunction (ejection fraction \< 40%), * scheduled for elective CABG surgery

Exclusion criteria

* associated chronic stroke, TIA , carotid occlusive disease( due to abnormal vasomotor activity), patients with known neurological impairment (cerebral infarction , dementia ), significant carotid artery stenosis , * valvular heart disease, * persistent arrhythmias, * congestive cardiac failure, * on mechanical ventilation, * intra-aortic balloon pump, * emergency surgery, * and those with known allergy to any of the study's drugs, * severe systemic non-cardiac disease and * patients with baseline NIRS reading \< 60% * Patients with dementia or visual or auditory impairment

Design outcomes

Primary

MeasureTime frameDescription
average postinduction NIRSevery 5 min after induction of anesthesia until 20 min afteraverage values of NIRS reading after induction of anesthesia

Secondary

MeasureTime frameDescription
mean arterial pressureevery minute after induction of anesthesia until 20 min after inductioninvasive mean arterial pressure
heart rateevery minute after induction of anesthesia until 20 min after inductionbpm
NRISduring induction, 1 min after induction, during intubation, then every 5 minutes for 20 minaverage of left and right side reading
cerebral hypoperfusionduring induction, 1 min after induction, during intubation, then every 5 minutes for 20 minNIRS\<60% or \<90% of baseline reading
hypotensionimmediately after induction of anesthesia until 20 min after inductionmean arterial pressure \<70% of baseline or \<65 mmHg
extra fentanyl bolusimmediately after induction of anesthesia until 20 min after inductionmcg
postoperative myocardial infarctionafter extubation until 30 days postoperativeelevated troponin and new ECG changes
postoperative strokeafter extubation until 30 days postoperativenew neurologic deficit
postoperative acute kidney injuryafter extubation until 30 days postoperative
wound infectionafter extubation until 30 days postoperative
renal replacement therapyafter extubation until 30 days postoperative

Countries

Egypt

Contacts

CONTACTMaha Mostafa
maha.mostafa@cu.edu.eg+201000365115

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026